Cytokeratin 5 Monoclonal Antibody (XM26) | Invitrogen MA5-12596 product information

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

antibody

product name :

Cytokeratin 5 Monoclonal Antibody (XM26)

catalog :

MA5-12596

quantity :

500 µL

price :

US 395.00

clonality :

monoclonal

host :

mouse

conjugate :

nonconjugated

clone name :

XM26

reactivity :

human, mouse

application :

western blot, immunohistochemistry, immunocytochemistry, immunoprecipitation, immunohistochemistry - paraffin section

more info or order :

Invitrogen product webpage

citations: 39

Published Application/Species/Sample/Dilution	Reference
immunohistochemistry - paraffin section; human; fig 1a	Gomi K, Tang Y, Arbelaez V, Crystal R, Walters M. Endothelial Cell Mediated Promotion of Ciliated Cell Differentiation of Human Airway Basal Cells via Insulin and Insulin-Like Growth Factor 1 Receptor Mediated Signaling. Stem Cell Rev. 2017;13:309-317 pubmed publisher
immunohistochemistry - paraffin section; human; 1:100; loading ...; fig 3a	Fang W, Yao M, Brummer G, Acevedo D, Alhakamy N, Berkland C, et al. Targeted gene silencing of CCL2 inhibits triple negative breast cancer progression by blocking cancer stem cell renewal and M2 macrophage recruitment. Oncotarget. 2016;7:49349-49367 pubmed publisher
immunocytochemistry; human; fig 2a western blot; human; fig 3h	Kuga T, Sasaki M, Mikami T, Miake Y, Adachi J, Shimizu M, et al. FAM83H and casein kinase I regulate the organization of the keratin cytoskeleton and formation of desmosomes. Sci Rep. 2016;6:26557 pubmed publisher
immunohistochemistry - paraffin section; mouse; 1:20; fig 1	Wang S, Liu J, Kim D, Datti A, Zacksenhaus E. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer. Breast Cancer Res. 2016;18:9 pubmed publisher
immunocytochemistry; human; fig 5	Goodman C, Sato T, Peck A, Girondo M, Yang N, Liu C, et al. Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism. Oncogene. 2016;35:1373-85 pubmed publisher
immunohistochemistry - paraffin section; human; fig s9	Liu H, Du L, Wang R, Wei C, Liu B, Zhu L, et al. High frequency of loss of PTEN expression in human solid salivary adenoid cystic carcinoma and its implication for targeted therapy. Oncotarget. 2015;6:11477-91 pubmed
immunohistochemistry - paraffin section; human; 1:100; tbl 2	Syed B, Green A, Nolan C, Morgan D, Ellis I, Cheung K. Biological characteristics and clinical outcome of triple negative primary breast cancer in older women - comparison with their younger counterparts. PLoS ONE. 2014;9:e100573 pubmed publisher
immunohistochemistry; human; 200 mg/ml	Mitchell D, Israr M, Alam S, Dinello D, Kishel J, Jia R, et al. HIV nucleoside reverse transcriptase inhibitors efavirenz and tenofovir change the growth and differentiation of primary gingival epithelium. HIV Med. 2014;15:196-202 pubmed publisher
immunohistochemistry; human; 1:200	Gremel G, Bergman J, Djureinovic D, Edqvist P, Maindad V, Bharambe B, et al. A systematic analysis of commonly used antibodies in cancer diagnostics. Histopathology. 2014;64:293-305 pubmed publisher
immunoprecipitation; human; 1:50	Perez A, Rocha R, Balabram D, Souza Á, Gobbi H. Immunohistochemical profile of high-grade ductal carcinoma in situ of the breast. Clinics (Sao Paulo). 2013;68:674-8 pubmed publisher
immunocytochemistry; human immunohistochemistry; human; 1:200 western blot; human	Sato T, Tran T, Peck A, Girondo M, Liu C, Goodman C, et al. Prolactin suppresses a progestin-induced CK5-positive cell population in luminal breast cancer through inhibition of progestin-driven BCL6 expression. Oncogene. 2014;33:2215-24 pubmed publisher
immunohistochemistry - paraffin section; human; 1:300; fig 3	Corrêa N, Kuasne H, Faria J, Seixas C, Santos I, Abreu F, et al. Genomic and phenotypic profiles of two Brazilian breast cancer cell lines derived from primary human tumors. Oncol Rep. 2013;29:1299-307 pubmed publisher
immunohistochemistry; human; 1:40	Niemiec J, Adamczyk A, Małecki K, Ambicka A, Rys J. Tumor grade and matrix metalloproteinase 2 expression in stromal fibroblasts help to stratify the high-risk group of patients with early breast cancer identified on the basis of st Gallen recommendations. Clin Breast Cancer. 2013;13:119-28 pubmed publisher
immunohistochemistry; human; 200 mg/mL	Mitchell D, Israr M, Alam S, Kishel J, Dinello D, Meyers C. Effect of the HIV nucleoside reverse transcriptase inhibitor zidovudine on the growth and differentiation of primary gingival epithelium. HIV Med. 2012;13:276-90 pubmed publisher
immunohistochemistry; human; 1:250	Mackiewicz M, Huppi K, Pitt J, Dorsey T, Ambs S, Caplen N. Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA. Breast Cancer Res Treat. 2011;130:663-79 pubmed publisher
immunohistochemistry; human	Garcia M, Santiago J, Terron A, Hernandez Martin A, Vicente A, Fortuny C, et al. Two novel recessive mutations in KRT14 identified in a cohort of 21 Spanish families with epidermolysis bullosa simplex. Br J Dermatol. 2011;165:683-92 pubmed publisher
immunohistochemistry; human; 1:50	Martins D, Sousa B, Lopes N, Gomes M, Veronese L, Albergaria A, et al. Molecular phenotypes of matched in situ and invasive components of breast carcinomas. Hum Pathol. 2011;42:1438-46 pubmed publisher
immunohistochemistry; human	Eloy C, Vinagre J, Cameselle Teijeiro J, Paiva M, Soares P, Sobrinho Simoes M. Tumor-in-tumor of the thyroid with basaloid differentiation: a lesion with a solid cell nest neoplastic component?. Int J Surg Pathol. 2011;19:276-80 pubmed publisher
immunohistochemistry; human	Rezze G, Fregnani J, Duprat J, Landman G. Cell adhesion and communication proteins are differentially expressed in melanoma progression model. Hum Pathol. 2011;42:409-18 pubmed publisher
immunohistochemistry; human; 1:250	Glynn S, Boersma B, Dorsey T, Yi M, Yfantis H, Ridnour L, et al. Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients. J Clin Invest. 2010;120:3843-54 pubmed publisher
immunohistochemistry; human	Israr M, Mitchell D, Alam S, Dinello D, Kishel J, Meyers C. The HIV protease inhibitor lopinavir/ritonavir (Kaletra) alters the growth, differentiation and proliferation of primary gingival epithelium. HIV Med. 2011;12:145-56 pubmed publisher
immunohistochemistry; human	Carvalho L, Pereira E, Frappart L, Boniol M, Bernardo W, Tarricone V, et al. Molecular characterization of breast cancer in young Brazilian women. Rev Assoc Med Bras (1992). 2010;56:278-87 pubmed
immunohistochemistry; human; 1:50	Lopes N, Sousa B, Vieira D, Milanezi F, Schmitt F. Vessel density assessed by endoglin expression in breast carcinomas with different expression profiles. Histopathology. 2009;55:594-9 pubmed publisher
immunohistochemistry; human	Gonzalez L, Corte M, Junquera S, González Fernández R, del Casar J, Garcia C, et al. Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma. Hum Pathol. 2009;40:1224-33 pubmed publisher
immunohistochemistry; human; 1:50	Dufloth R, Alves J, Martins D, Vieira D, Chikota H, Zeferino L, et al. Cytological criteria to predict basal phenotype of breast carcinomas. Diagn Cytopathol. 2009;37:809-14 pubmed publisher
immunohistochemistry; human; 1:250	Martin D, Boersma B, Yi M, Reimers M, Howe T, Yfantis H, et al. Differences in the tumor microenvironment between African-American and European-American breast cancer patients. PLoS ONE. 2009;4:e4531 pubmed publisher
immunohistochemistry; human; 1:25	Bori R, Cserni G. Basal phenotype in breast carcinoma occurring in women aged 35 or younger. Pathol Oncol Res. 2009;15:41-5 pubmed publisher
immunohistochemistry; human; 1:25	Gama A, Alves A, Schmitt F. Identification of molecular phenotypes in canine mammary carcinomas with clinical implications: application of the human classification. Virchows Arch. 2008;453:123-32 pubmed publisher
immunohistochemistry; human	Trompetter M, Smedts F, van der Wijk J, Schoots C, de Jong H, Hopman A, et al. Keratin profiling in the developing human prostate. A different approach to understanding epithelial lineage. Anticancer Res. 2008;28:237-43 pubmed
immunohistochemistry; human; 1:80	Dufloth R, Matos I, Schmitt F, Zeferino L. Tissue microarrays for testing basal biomarkers in familial breast cancer cases. Sao Paulo Med J. 2007;125:226-30 pubmed
immunohistochemistry; human; 1:25	Li H, Cherukuri P, Li N, Cowling V, Spinella M, Cole M, et al. Nestin is expressed in the basal/myoepithelial layer of the mammary gland and is a selective marker of basal epithelial breast tumors. Cancer Res. 2007;67:501-10 pubmed
immunohistochemistry; human; 1:50	Paredes J, Lopes N, Milanezi F, Schmitt F. P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ. Virchows Arch. 2007;450:73-80 pubmed
immunohistochemistry; human; 1:80	Matos I, Dufloth R, Alvarenga M, Zeferino L, Schmitt F. p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch. 2005;447:688-94 pubmed
	Hao S, Ning K, Kuz C, Vorhies K, Yan Z, Qiu J. Long-Term Modeling of SARS-CoV-2 Infection of In Vitro Cultured Polarized Human Airway Epithelium. MBio. 2020;11: pubmed publisher
	Hao S, Ning K, Kuz C, Vorhies K, Yan Z, Qiu J. Long Period Modeling SARS-CoV-2 Infection of in Vitro Cultured Polarized Human Airway Epithelium. bioRxiv. 2020;: pubmed publisher
	Brummer G, Acevedo D, Hu Q, Portsche M, Fang W, Yao M, et al. Chemokine Signaling Facilitates Early-Stage Breast Cancer Survival and Invasion through Fibroblast-Dependent Mechanisms. Mol Cancer Res. 2018;16:296-308 pubmed publisher
	Yao M, Smart C, Hu Q, Cheng N. Continuous Delivery of Neutralizing Antibodies Elevate CCL2 Levels in Mice Bearing MCF10CA1d Breast Tumor Xenografts. Transl Oncol. 2017;10:734-743 pubmed publisher
	Behbod F, Kittrell F, LaMarca H, Edwards D, Kerbawy S, Heestand J, et al. An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ. Breast Cancer Res. 2009;11:R66 pubmed publisher
	Fukui D, Bando G, Ishikawa Y, Kadota K. Adenosquamous carcinoma with cilium formation, mucin production and keratinization in the nasal cavity of a red fox (Vulpes vulpes schrencki). J Comp Pathol. 2007;137:142-5 pubmed

image

image 1 :

Formalin-fixed, paraffin-embedded human mesothelioma stained with Keratin 5 antibody using peroxidase-conjugate and AEC chromogen. Note cytoplasmic staining of tumor cells.

product information

Product Type :

Antibody

Product Name :

Cytokeratin 5 Monoclonal Antibody (XM26)

Catalog # :

MA5-12596

Quantity :

500 µL

Price :

US 395.00

Clonality :

Monoclonal

Host :

Mouse

Reactivity :

Human

Applications :

Immunocytochemistry: 1:200-1:250, Immunohistochemistry (Paraffin): 1:20, Immunohistochemistry: 1:50, Western Blot: 1:1,000

Species :

Human

Clone :

XM26

Isotype :

IgG1, kappa

Storage :

4° C

Description :

Cytokeratin pan is part of a subfamily of intermediate filament proteins that are characterized by remarkable biochemical diversity, and represented in human epithelial tissues by at least 20 different polypeptides. Cytokeratins range in molecular weight between 40 kDa- 68 kDa, and an isoelectric pH between 4.9-7.8. The individual human cytokeratins are numbered 1 to 20. The various epithelia in the human body usually express cytokeratins which are not only characteristic of the type of epithelium, but also related to the degree of maturation or differentiation within an epithelium. Cytokeratin subtype expression patterns are used to an increasing extent in the distinction of different types of epithelial malignancies. The cytokeratin antibodies are not only of assistance in the differential diagnosis of tumors using immunohistochemistry on tissue sections, but are also a useful tool in cytopathology and flow cytometric assays. The composition of cytokeratin pairs vary with the epithelial cell type, stage of differentiation, cellular growth environment, and disease state. Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis.

Immunogen :

Recombinant protein corresponding to C-terminal 103 aa of cytokeratin 5

Format :

Liquid

Applications w/Dilutions :

Immunocytochemistry: 1:200-1:250, Immunohistochemistry (Paraffin): 1:20, Immunohistochemistry: 1:50, Western Blot: 1:1,000

Aliases :

3300001P10Rik; 58 kDa cytokeratin; alpha keratin; AW146334; C DDD; C KRT5A; CK5; CK-5; ckii; ckii protein; cytokeratin 5; cytokeratin-5; DDD; DDD1; EBS2; epidermolysis bullosa simplex 2 Dowling-Meara/Kobner/Weber-Cockayne types; K5; keratin 5; keratin 5 (epidermolysis bullosa simplex Dowling-Meara/Kobner/Weber-Cockayne types); keratin 5 (epidermolysis bullosa simplex, Dowling-Meara/Kobner/Weber-Cockayne types); keratin 5, type II; keratin complex 2, basic, gene 5; keratin type II, tail domain; keratin, type II cytoskeletal 5; keratin, type II cytoskeletal 5; keratin 5; keratin-5; Krt2-5; KRT5; KRT5A; Sak57; Tfip8; tuftelin interacting protein 8; type II alpha-keratin IIA; type II cytokeratin; type-II keratin Kb5; wu:fb02h09; wu:fj02d02; wu:fk78b12; zfCKII

more info or order :

Invitrogen product webpage